Log in
Enquire now
‌

PLCC2 LLC SBIR Phase II Award, March 2021

A SBIR Phase II contract was awarded to Physical Sciences in March, 2021 for $678,314.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.

OverviewStructured DataIssuesContributors

Contents

sbir.gov/node/2189947
Is a
SBIR/STTR Awards
SBIR/STTR Awards

SBIR/STTR Award attributes

SBIR/STTR Award Recipient
Physical Sciences
Physical Sciences
0
Government Agency
0
Government Branch
National Institutes of Health
National Institutes of Health
0
Award Type
SBIR0
Contract Number (US Government)
4R44EY030812-020
Award Phase
Phase II0
Award Amount (USD)
678,3140
Date Awarded
March 1, 2021
0
End Date
February 28, 2023
0
Abstract

Project Summary/AbstractPhysical Sciences Inc. (PSI) in collaboration with New York University (NYU) School of Medicine proposes to develop a novel ophthalmic imaging platform for characterizing retinal morphology and monitoring ocular blood flow abnormalities. This platform will combine non-invasive measurements of retina/choroid structure and ocular blood flow based on optical coherence tomography (OCT) and wide- field semi-quantitative global flow visualization using line-scanning Doppler flowmetry (LSDF). The combination of these two imaging modalities within the same imaging platform enables comprehensive assessment of blood flow in the retina and choroid. This novel imaging platform will enable imaging studies in animals and human subjects with normal vision or with various retinal diseases. Prior PSI experience in developing advanced ophthalmic imaging systems coupled with our collaboratorsandapos; expertise in Ophthalmology will be leveraged to ensure the successful outcome of this important Randamp;D program.A feasibility study will be performed during the Phase I program by imaging normal and diseased rodent models using a benchtop instrument. A clinical prototype instrument will be manufactured and tested clinically in Phase II in the NYU population of patients to highlight hemodynamic retinal biomarkers. We choose to focus on diseases that are the leading causes of blindness including, age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma to demonstrate the clinical utility of our novel system. We will recruit healthy individuals to set a reference, and subjects with AMD, DR, and glaucoma at a wide range of disease severity. In all of these conditions, the ability to record in vivo blood flow will provide novel information that will open new diagnostic and treatment avenues.Project NarrativeDegenerative neurovascular diseases of the eye often have either hemodynamic consequences or causes, though the mechanisms are poorly understood. Improved blood flow imaging diagnostics will aid in the detection and management of many eye conditions, and foster new research for understanding the major causes of blindness: AMD, DR, and glaucoma.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like PLCC2 LLC SBIR Phase II Award, March 2021

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.